Loading patent…
AssigneeMthera Pharma Co., Ltd.
InventorsMiwon SOHN, Jin Gyu CHOI, Sinyeon KIM, Sang Cheol PARK, Dong Hyun KIM, Sun Yeou KIM, Seong Min HONG, Myung Sook OH, In Gyoung JU, Choong Hwan LEE
Estimating the term…
The present invention relates to a novel Lactobacillus paracasei NK112 strain that has the effect of preventing or treating cognitive dysfunction and intestinal dysfunction. In addition, the present invention relates to a composition for prevention, treatment, or alleviation of cognitive dysfunction and intestinal dysfunction, comprising a Lactobacillus paracasei NK112 strain, a Cuscuta australis R.Br. extract, and a Cuscuta japonica Choisy extract. The strain and the composition, of the present invention, exhibit efficacy in increasing the expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), alleviating intestinal inflammation, and the like, and thus can be effectively used in the prevention or treatment of cognitive dysfunction and intestinal dysfunction.
A Lactobacillus paracasei NK112 strain deposited under the accession number:
A pharmaceutical composition for prevention or treatment of cognitive dysfunction or intestinal dysfunction, comprising at least one selected from the group consisting of a Lactobacillus paracasei NK112 strain, a Cuscuta australis R.Br. extract, and a Cuscuta japonica Choisy extract.
A food composition for prevention or alleviation of cognitive dysfunction or intestinal dysfunction, comprising at least one selected from the group consisting of a Lactobacillus paracasei NK112 strain, a Cuscuta australis R.Br. extract, and a Cuscuta japonica Choisy extract.
An animal feed composition for prevention or alleviation of cognitive dysfunction or intestinal dysfunction, comprising at least one selected from the group consisting of a Lactobacillus paracasei NK112 strain, a Cuscuta australis R.Br. extract, and a Cuscuta japonica Choisy extract.
Dependencies are inferred from the claim text.